Breast cancer remains a significant burden on human health. Almost 250,000 US women will be diagnosed this year and approximately 40,000 women will die. ER/PR+ (endocrine responsive) Her2- tumors occur in approximately 90,000 breast cancer patients each year, of which 20,000 develop drug resistance. For these patients, despite advances in available drugs, the best existing solutions do not provide durable arrest of the tumors. The patient becomes resistant to the drug and overall survival rates are unchanged.

Concarlo Holdings, LLC (Concarlo) is an oncology company focused on diagnosing and treating cancer by targeting a unique cellular pathway. Our approach is based on the role of p27Kip1 — a key “ON-OFF” switch that modulates the activities of critical proteins involved in many cancers: CDK4, CDK6, and CDK2. Concarlo is commercializing therapeutics to treat metastatic cancer alongside a diagnostic to identify patients who will respond to therapy.